LitAlert ~~ GeneLit.com

    • Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    • Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Bloomfield R, Goble S, Wang P, Glasspool RM, Scott CL, the Gynecologic Cancer Intergroup Meta-Analysis Committee.
    • Cancer. 2021 Mar 19. doi: 10.1002/cncr.33517. Epub ahead of print
    • Population-Based Estimates of the Age-Specific Cumulative Risk of Breast Cancer for Pathogenic Variants in CHEK2: Findings from the Australian Breast Cancer Family Registry.
    • Nguyen-Dumont T, Dowty JG, Steen JA, Renault AL, Hammet F, Mahmoodi M, Theys D, Rewse A, Tsimiklis H, Winship IM, Giles GG, Milne RL, Hopper JL, Southey MC.
    • Cancers (Basel). 2021 Mar 18;13(6):E1378. doi: 10.3390/cancers13061378.
    • Genetic testing and surgical treatment after breast cancer diagnosis: Results from a national online cohort.
    • Verdial FC, Bartek MA, Anderson BO, Javid SH.
    • J Surg Oncol. 2021 Mar 18. doi: 10.1002/jso.26372. Epub ahead of print.
    • Breast cancer worry in higher-risk women offered preventive therapy: a UK multicentre prospective study.
    • Lloyd KE, Hall LH, Ziegler L, Smith SG; ENGAGE investigators.
    • Breast Cancer Res Treat. 2021 Mar 17. doi: 10.1007/s10549-021-06183-x. Epub ahead of print.
    • Familial pancreatic cancer: who should be considered for genetic testing?
    • Kartal K, Guan Z, Tang R, Griffin M, Wang Y, Braun D, Klein AP, Hughes KS.
    • Ir J Med Sci. 2021 Mar 17. doi: 10.1007/s11845-021-02572-9. Epub ahead of print.
    • Evaluation of online Spanish and English health materials for preventive mastectomy. are we providing adequate information?
    • Del Valle DD, Pardo JA, Maselli AM, Valero MG, Fan B, Seyidova N, James TA, Lee BT.
    • Breast Cancer Res Treat. 2021 Mar 15. doi: 10.1007/s10549-021-06171-1. Epub ahead of print.
    • Review
    • Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years.
    • Desai NV, Yadav S, Batalini F, Couch FJ, Tung NM.
    • Cancer. 2021 Mar 15;127(6):828-833. doi: 10.1002/cncr.33305. Epub 2020 Nov 4.
    • Commentary
    • Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors.
    • Nero C, Ciccarone F, Pietragalla A, Duranti S, Daniele G, Salutari V, Carbone MV, Scambia G, Domenica Lorusso D.
    • Cancers (Basel). 2021 Mar 15;13(6):E1298S. doi: 10.3390/cancers13061298.